Novel test may predict adverse events with, recurrence after immunotherapy
Source: Healio, September 2022
An experimental test may help predict which patients with cancer may develop disease recurrence after immunotherapy treatment, according to study results published in Clinical Cancer Research.
The test also may help predict which patients may experience severe adverse events with immunotherapy.
Researchers analyzed pretreatment serum from 950 patients who had undergone resection for melanoma who participated in randomized phase 3 trials of adjuvant immunotherapy. One trial, CheckMate 238, compared the anti-CTLA-4 antibody ipilimumab (Yervoy, Bristol Myers Squibb) with the PD-1 inhibitor nivolumab (Opdivo, Bristol Myers Squibb). The other trial, CheckMate 915, compared nivolumab monotherapy with an ipilimumab-nivolumab combination.